Good evening :)
Switch to
Place Order

Bafna Pharmaceuticals Ltd

BAFNAPH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹368 cr, stock is ranked 1,297
High RiskStock is 3.69x as volatile as Nifty
155.906.30 (-3.88%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹368 cr, stock is ranked 1,297
High RiskStock is 3.69x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
63.26
PB RatioPB Ratio
6.50
Dividend YieldDiv. Yield
Sector PESector PE
40.61
Sector PBSector PB
5.75
Sector Div YldSctr Div Yld
0.62%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202178.5045.0342.7371.97-16.73-18.87-24.735.83
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 2.25%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Related Party Transactions 
Announced OnJul 9, 2021

Bafna Pharmaceuticals Limited has informed the Exchange about related Party Transactions | Download

Bafna Pharmaceuticals Limited has informed the Exchange about related Party Transactions | Download

Reply to Clarification- Financial results 
Announced OnJun 29, 2021

The Exchange had sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone auditors report not submitted. The response of the Company is enclosed. | Download

The Exchange had sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone auditors report not submitted. The response of the Company is enclosed. | Download

Cash Dividend 
Ex. DateSep 19, 2013

Final • Div/Share: ₹ 0.6

See all events